Rebif (human IFN-β-1a) / EMD Serono  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rebif (human IFN-β-1a) / EMD Serono
ACTRN12622000258752: INFINiTE-CV2 Phase IIa Trial: INterFeron type 1 Intra-Nasal gel Therapy for Early treatment of SARS-CoV2 (COVID-19)

Not yet recruiting
2
100
 
IntraVital, IntraVital Pty Ltd
COVID-19
 
 
2008-005656-24: ENSAYO CLÍNICO SOBRE LA EVOLUCIÓN Y EL IMPACTO DEL TRATAMIENTO FARMACOLÓGICO EN LA PERDIDA AXONAL PROGRESIVA EN PACIENTES QUE CON ESCLEROSIS MÚLTIPLE QUE HAN PRESENTADO UN PRIMER EPISODIO DESMIELINIZANTE

Ongoing
2
20
Europe
REBIF 22 microgramos solución inyectable, REBIF 22 microgramos solución inyectable
Dra. Rosario Blasco
Primer episodio desmielinizante con criterios de esclerosis múltiple (EM) confirmada por laboratorio que no haya consistido en neuritis óptica y que no tengan criterios de mal pronóstico definidos como: 9 ó +lesiones y/o lesiones que capten Gd, afectación cerebelosa, EDSS>2 a las tres semanas del inicio del episodio.
 
 
2020-003872-42: Antiviral and Immunomodulatory Interferon-Beta in high-risk COVID-19 patients Valutazione dell’attività antivirale e immunomodulatoria di Interferone-Beta in pazienti COVID-19 anziani

Ongoing
2
60
Europe
Interferon beta-1a, [IFNb], Solution for injection, REBIF - 22 MCG/0.5 ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - CARTUCCIA (VETRO) - 1.5 ML (12 MILIONI UI/ML) 4 CARTUCCE
Istituto di Farmacologia Traslazionale - CNR, Regione Lazio, Istituto Nazionale per le malattie infettive "Lazzaro Spallanzani", Merck Healthcare KGaA, Istituto Superiore di Sanità, Istituto di Farmacologia Traslazionale - CNR
SARS-CoV 2 infection characterized by a National Early Warning Score lower or equal to 2 and symptoms present for less than 7 days Infezione da virus SARS-CoV 2 con sintomatologia presente da meno di 7 giorni e punteggio minore o uguale a 2 nella National Early Warning Score (NEWS), Early SARS-CoV 2 infection characterized by mild COVID-19 symptoms Stato iniziale di infezione da virus SARS-CoV 2 con sintomi lievi di COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
NCT05298670: Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients

Recruiting
2
80
RoW
MetFORMIN 1000 Mg Oral Tablet, Cidophage ®1000 mg tablets, CID, Giza, Egypt) tablet and Rebiff ® 44mcg or Avonex®, Interferon beta-1a, Rebiff ® 44mcg or Avonex®
German University in Cairo
Multiple Sclerosis
02/23
03/23
NCT04079088: Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Withdrawn
2
300
NA
Placebo, BIIB061, Interferon-beta1, Avonex, Plegridy, Betaferon/Betaseron, Extavia, or Rebif, Glatiramer acetate, Copaxone, Glatopa
Biogen
Relapsing Multiple Sclerosis
09/24
09/24
NPC-Nivo, NCT06019130: Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

Recruiting
2
57
Europe
Nivolumab, Opdivo, Cisplatin, Cisplatin Teva, 5-Fluorouracil, Fluorouracil-GRY, Gemcitabine, Gemcitabin-GRY, Radiotherapy, Interferon beta-1a, Rebif, MRI, PET, Patient-Reported Outcomes
German Society for Pediatric Oncology and Hematology GPOH gGmbH, Deutsche Krebshilfe e.V., Bonn (Germany)
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms, Nasopharynx Cancer
01/26
01/28
NCT02330393: Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

Not yet recruiting
1/2
20
US
Anti-PD-L1 Monoclonal Antibody MSB0010718C, MSB0010718C, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RT, Recombinant Interferon Beta, Betantrone, Betaseron, Feron, IFN-B, Rebif, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells, MCPyV TAg-specific polyclonal autologous CD8-positive T cells, Laboratory Biomarker Analysis
Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI)
Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma
01/19
 
NCT05936229: Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Not yet recruiting
1/2
24
US
Interferon Beta-1A, 145258-61-3, Avonex, BG9418, Rebif, Recombinant interferon beta-1a, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Computed Tomography, CAT Scan, Computed Axial Tomography, Computerized axial tomography (procedure), Positron Emission Tomography, Pet Scan, Positron emission tomography (procedure), Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Lumbar Puncture, LP, spinal tap, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection, Biological Sample Collection, Biopsy, BIOPSY_TYPE, Bx
Fred Hutchinson Cancer Center, Faron Pharmaceuticals Ltd
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
10/27
10/27

Download Options